Cancer drugs

Cancer drugs

Drugs, agents used in the treatment of cancer or conditions related to cancer.

Industry: Pharmaceutical

Add a new term

Contributors in Cancer drugs

Become a Contributors

Cancer drugs

Smoothened antagonist LDE225

Pharmaceutical; Cancer drugs

An orally bioavailable small-molecule Smoothened (Smo) antagonist with potential antineoplastic activity. Smoothened antagonist LDE225 selectively binds to the Hedgehog (Hh)-ligand cell surface ...

Smoothened antagonist LEQ506

Pharmaceutical; Cancer drugs

An orally bioavailable small-molecule Smoothened (Smo) antagonist with potential antineoplastic activity. Smoothened antagonist LEQ506 selectively binds to the Hedgehog (Hh)-ligand cell surface ...

Vascular disrupting agent CYT997

An orally bioavailable small-molecule with tubulin-inhibiting, vascular-disrupting, and potential antineoplastic activities. Vascular disrupting agent (VDA) CYT997 inhibits tubulin polymerization in ...

PI3K inhibitor BKM120

Pharmaceutical; Cancer drugs

An orally bioavailable specific oral inhibitor of the pan-class I phosphatidylinositol 3-kinase (PI3K) family of lipid kinases with potential antineoplastic activity. PI3K inhibitor BKM120 ...

Tacedinaline

Pharmaceutical; Cancer drugs

An orally bioavailable substituted benzamide derivative with potential antineoplastic activity. Tacedinaline inhibits histone deacetylation, which may result in histone hyperacetylation, followed by ...

SMAC mimetic LCL161

Pharmaceutical; Cancer drugs

An orally bioavailable second mitochondrial-derived activator of caspases (SMAC) mimetic and inhibitor of IAP (Inhibitor of Apoptosis Protein) family of proteins, with potential antineoplastic ...

FAK inhibitor PF-00562271

Pharmaceutical; Cancer drugs

An orally bioavailable small molecule and ATP-competitive focal adhesion kinase (FAK) inhibitor with potential antineoplastic and antiangiogenic activities. FAK inhibitor PF-00562271 inhibits the ...